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A B S T R A C T
This article provides an update on photodynamic therapy by discussing each of the essential components in sequence:
mechanisms of action, common photosensitizers, typical light sources, and indications. In dermatology, photodynamic
therapy (PDT) is mainly used in the treatment of superficial skin cancers: actinic keratoses, Bowen’s disease and superfi-
cial basal cell carcinomas. However, the range of indications has been expanding continuously. PDT is also used for the
treatment of other oncological indications and non-malignant conditions such as acne vulgaris and photoaged skin. The
5-aminolevulinic acid (ALA) or its methyl ester (MAL) is applied topically as photosensitizer before activation with visi-
ble light. The advantages of topical PDT are: ability to treat multiple lesions simultaneously, low invasiveness, good tol-
erance and excellent cosmetic results.
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Introduction
Although a relatively novel procedure, photodynamic
therapy (PDT) has enjoyed increased importance in the
management of skin disease, including therapy and pre-
vention, during last decades. PDT involves the light that
actives a photosensitizer resulting in the formation of
cytotoxic reactive oxygen species in diseased tissue. The
aim is selective destruction of premalignant and malig-
nant cells with the preservation of surrounding normal
cells1–4.
The photosensitizers are systemic and topical. Porfi-
mer sodium (Photofrin) is a hematoporphyrin derivate
used intravenous5. It is rarely used as the photosensi-
tivity remains for several weeks6. Second generation of
systemic photosensitizers have faster and selective tissue
accumulation with shorter half-life7. The topically used
photosensitizers in dermatology are 5-aminolevulinic
acid (5-ALA) and its ethylated ester methyl aminole-
vulinic acid (MAL). MAL has a more selective accumula-
tion of porphyrin in premalignant and malignant skin
cells1,8–12; it is more lipophilic and therefore it may pene-
trate more deeply into lesions and also more rapidly
achieves the maximum in intracellular protoporphyrin
concentration which leads to a shorter incubation time of
three hours compared with ALA13,14. Additionally, the us-
age of liposomal vehicle or nanocolloical ALA prepara-
tions might greatly reduce the concentration of ALA
with still good penetration and accumulation in tumor
cells13,15. 5-ALA and MAL itself are not photosensitizers.
They are precursors of the intrinsic intracellular heme
biosynthetic pathway, which results in the production of
photoactive porphyrins16. Following application, 5 ALA
and MAL are converted into mainly Protoporphyrin IX
but also in other intermediate photosensitizing porphy-
rins that are essential for the transfer of singlet oxygen
species and the generation of free radicals. Although
PDT results in singlet oxygen species and free radical
formation, these species are relatively short lived, with a
radius of only 0.01 mm, and thus have low mutagenic po-
tential for nonlocalized DNA damage8. Formed singlet
oxygen reacts with lipids, proteins and nucleic acids and
is essential for tumors` cell damage17,18. Moreover, as the
porphyrins are synthesized in mitochondria, the primary
damage is in mitochondria19,20. Other mechanism such as
apoptosis, necrosis and vascular damage are also in-
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volved. Apoptosis is more important molecular mecha-
nism of tumors cell damage than necrosis17,19-21. Addi-
tionally, inflammatory reaction with histamine and other
vasoactiv amines, cytokines are involved22-27. Moreover,
with systemic PDT there is indirect mechanic with dam-
age of blood vessels and ischemia28-30.
Light Sources
For optimal photosensitize excitation and tissue pene-
tration the right light source is essential1,2,7,31–32. In PDT
the wave lights from 400–700 nm are used with absorp-
tion peak in 405 nm (blue region of sorest band5,33–35. Ad-
ditionally, there are smaller absorption peaks at 505, 540,
580 and 635 nm. The 635 nm absorption peak in the red
region has better tissue penetration36,37. And therefore is
used in therapy of skin tumors up to 2 to 3-mm depth
while blue light can be used in therapy of actinic kurtosis
(AK)4,33.
Light sources for PDT are coherent and incoherent
broadband lights.
Lasers as coherent sources are »metal vapor« lasers
(copper and gold vapor), dye pumped tunable (argon-dye,
neodymium:YAG-dye) lasers and diode lasers. Their ad-
vantage is seen in therapy of smaller lesions, in shorter
irradiation time, and in the use of monochromatic light38,39.
Incoherent light sources are fluorescent lamps, light
emitting diodes (LED), filtered xenon arc and metal halid
light. LED are broadband source convenient for therapy
of wider area, bigger and multiple tumors and represents
„golden standard«in topical PDT33.
Indications and potential oncological5,33,34,40–42 and
non-oncological43–47 indications for PDT are AK, Bowen
disease (BD), basal cell carcinoma (BCC), squamous cell
carcinoma (SCC), cutaneous T-cell lymphoma (CTCL),
Kaposi sarcoma, keratoacanthoma, metastasis carcino-
ma, extramammary Paget's disease, acne, hirsutism, vi-
ral and genital warts, cutaneous leishmaniasis, localized
scleroderma, cutaneous sarcoidosis, psoriasis vulgaris,
and photorejuvenation.
Contraindications
Contraindications for PDT are porphyria, allergy and
photoallergy on photosensitizer48–51.
The most common and troublesome acute adverse
event of topical PDT is the burning and stinging pain
that occurs during light exposure, and may continue af-
ter exposure. Pain is restricted to the illuminated area
and may reflect nerve stimulation and /or tissue damage
by ROS, possibly aggravated by hyperthermia4. The pain
is stronger with larger and ulcerated lesions and lesions
on the head33,34. According to some studies ALA-PDT is
more painful during treatment52. The pain may be man-
aged with application of a topical mixture of lignocaine
and prilocaine or cold air analgesia53,54.
The incidence of scarring associated with topical PDT
is very low; usually there is good or excellent cosmetic
outcome4.
Postinflammatory hypopigmentation or hyperpig-
mentation can occur after 48–72 h and increases during
the 2 weeks following treatment55,56.
Hair loss is a potential side-effect of PDT but perma-
nent localized hair loss following PDT is uncommon57.
PDT treatment-related carcinogenesis is expected to
be low or absent compared with UV therapy as PDT does
not induce covalent modifications of DNA, formation of
ciklobutan pirimidin dimmers58–60. Moreover, porphyrin-
-like molecules also possess antioxidant and antimuta-
genic properties60. Preliminary data using PDT for che-
moprevention are promising, with anecdotal evidence
suggesting that this therapy may postpone the develop-
ment of actinic keratoses or nonmelanoma skin can-
cer2,31.
Following topical PDT, localized photosensitivity can
remain for up to 48 h61,62.
Indications
AK
The usage of PDT was first approved by FDA for ac-
tinic keratoses2,5. ALA/ MAL-PDT are highly effective for
multiple AK and areas of field cancerization and actinic
heilitis2,63–80. It can be considered as a first line therapy.
It can be used as a single treatment, repeated if neces-
sary after 3 months or even more treatments can be
done1,2. Complete response rates vary from 50–90% de-
pending on the photosensitizer, number and area of
treatment and type of illuminator2,4,32,69–82. Higher clear-
ance is seen on the face and scalp, in 71–100%; lesions on
acral sites showed lower clearance rates of 44–73% and
lower on the lips where more treatment sessions can be
applied or a larger area can be treated1,4,13, 32,83. Further-
more, it is more effective in thin and moderate thickness
AK while hyperkeratotic lesion show lower clearance be-
cause of lower penetration of 5-ALA5. Blue, green and
red light have been used with equal effectiveness76. Also
there was significant improvement in signs of photo-
aging63–68,70,71,73 that might be due to increase of type I
collagen seen in intense pulse light activation of ALA and
MAL, activation of specific molecular pathways and a
nonspecific immune response2,67,68. MAL-PDT for AK
showed less pain than ALA-PDT with the same light
source76. Effectiveness of topical PDT and cosmetic out-
come following PDT for AK is superior to cryotherapy.
BD
Topical PDT is an effective therapy for BD32,80,84–96,
particularly for large and multiple patch disease and for
lesions at unusual sites such as nipple87, subungual re-
gion88,89 and poor healing sites such as lower leg90, penis,
epidermolysis bullosa91, radiation dermatitis92, penis95
and fingers93 with equivalence to cryotherapy and equiv-
alence or superiority to topical 5-FU32,80,94–96. Further-
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more, it can be considered as a first line therapy; the
number of treatments were one to three1,9,32,84–98; cos-
metic outcome is superior to standard cryotherapy and
topical 5-FU therapy84,85,97 (Figures 1 and 2).
BCC
The original guidelines from 2002 concluded PDT to
be effective in superficial BCC, but that adjunctive ther-
apy might be required to enhance efficacy for nodular
BCC4. Further approaches taken in an attempt to in-
crease the response of BCC, particularly nodular lesions,
have been: the usage of the more lipophilic methyl ester
of ALA, MAL; routine usage double PDT treatments; the
lesion surface preparation with gentle scraping of super-
ficial lesions, while nodular lesions were prepared by re-
moving intact overlying epidermis with some debulking;
usage of fractionation of light32,99. Topical MAL–PDT
and ALA–PDT are highly effective treatments for super-
ficial BCC32. Topical MAL–PDT is effective in nodular
BCC, although with a lower efficacy than excision sur-
gery, and may be considered in situations where surgery
may be suboptimal39. Pigmented and morpheiform basa-
liomas are resistant to PDT5. In comparison with cryo-
therapy effectiveness of topical PDT and cosmetic out-
come following PDT is superior59 (Figures 3 and 4).
SCC
Current evidence supports the potential usage of topi-
cal PDT for superficial, microinvasive SCC limited to
papillary dermis, but in view of its metastatic potential,
topical PDT cannot currently be recommended for the
treatment of invasive SCC with further study requi-
red4,59.
CTCL
The selective uptake of photosensitizers into lympho-
cytes offers an explanation for the potential usage of
PDT in CTCL. Malignant T lymphocytes may be more
susceptible than keratinocytes to PDT-induced lysis, as
illustrated in a study using the novel photosensitizer sili-
con phthalocyanine32,59. In the limited number of studies
performed so far, indications were early stage localized
CTCL with multiple treatments usually required for
clearance78. Further studies of PDT for CTCL are re-
quired.
Photodynamic therapy for skin cancer prophylaxis
Current evidence indicates that topical PDT has the
potential to provide a preventive role against skin cancer.
The potential mechanism is selective destruction of kera-
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Fig. 1. Bowen’s disease (recurrence after surgical excision).
Fig. 2. After one treatment with ALA-PDT (photosenzitizer: 20%
5-ALA, light source: broadband Waldmann PDT 1200 lamp,
light dose: 150 J/cm2).
Fig. 3. Superficial basal cell carcinoma (recurrence after surgi-
cal excision).
Fig. 4. After two treatments with ALA-PDT (photosenzitizer: 20%
5-ALA, light source: broadband Waldmann PDT 1200 lamp,
light dose per session: 150 J/cm2).
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tinocytes bearing mutated p53 induced by UV exposure
or inducing an immune response against neoplastic cells
and acting as a biological response modifier55,56,78.
Photodynamic photorejuvenation
Standard topical PDT and ALA-IPL show the reduc-
tion of fine lines and wrinkles, photoaging, telangiecta-
sis, melasma, crow’s feet, dyspigmentation, and erythe-
ma63–68.
Acne and related conditions
PDT may promote improvement in acne via antibac-
terial activity against Propionibacterium acnes, selective
damage of sebaceous glands, and reduction in follicular
obstruction by keratinocyte shedding and via secondary
host responses78. Although topical PDT can improve in-
flammatory acne on the face and back, optimization of
protocols, to sustain response while minimizing adverse
effects such as induced skin exfoliation and hypepigmen-
tation, is awaited.
Conclusion
ALA or MAL PDT in dermatology is now a well-estab-
lished treatment option for AK, BD and superficial BCC.
In this indications PDT achieves similar clearance rates
compared with standard treatment modalities (surgical
excision, liquid nitrogen, 5-FU) and shows some impor-
tant advantages: possibility of simultaneous treatment of
multiple and large tumors, relatively short healing times,
good patient tolerance and an excellent cosmetic out-
come. If result are partial or in case of relapse PDT can
be repeated several times until clinical remission occurs
because it does not create cumulative toxicity. For other
cutaneous malignancies and non-oncological indications,
randomized, controlled studies are required which would
offer solid evidence of the effectiveness of PDT. In all,
PDT appears to be a valuable treatment option in derma-
tology and dermatologists must continue to strive to
make PDT global subspecialty of dermatology.
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FOTODINAMI^KA TERAPIJA U DERMATOLOGIJI: SADA[NJE PRIMJENE
I MOGU]NOSTI RAZVOJA
S A @ E T A K
U ~lanku se prikazuju mehanizami djelovanja fotodinami~ke terapije (FDT), fotosensitizatori, izvori svjetla i indi-
kacije za FDT. 5-aminolevuliniska kiselina i njezin metilni ester se koriste kao topi~ki fotosenzitizatori. Indikacije za
FDT u dermatologiji su prvenstveno povr{inski tumori ko`e: aktini~ke keratoze, Bowenova bolest i povr{inski bazo-
celularni karcinom. Nadalje, indikacije za FDT se stalno nadopunjuju te su pro{irene i na druge onkolo{ke i neonko-
lo{ke dijagnoze kao {to su vulgarne akne i fotostarenje ko`e. Prednost FDT terapije je u mogu}nsoti lije~enja multiplih
lezija, niska invazivnost, dobra tolerancija i izvrsni estetski rezultati.
K. Kostovi} et al.: Photodynamic Therapy and Dermatology, Skin Cancer, Coll. Antropol. 36 (2012) 4: 1477–1481
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